When was Tetraphase Pharmaceuticals founded?

Tetraphase Pharmaceuticals was founded in 2006 and raised its 1st funding round within a year of its incorporation.

Where is Tetraphase Pharmaceuticals located?

Tetraphase Pharmaceuticals is headquartered in Watertown, United States.

Who is the current CEO of Tetraphase Pharmaceuticals?

Guy Macdonald of Tetraphase Pharmaceuticals.

How many employees does Tetraphase Pharmaceuticals have?

As of Dec 31, 2020, the latest employee count at Tetraphase Pharmaceuticals is 31.

Is Tetraphase Pharmaceuticals a funded company?

Tetraphase Pharmaceuticals is a funded company, having raised a total of $80M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 2006.

When was the latest funding round of Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' latest funding was a $***** Post IPO round on Jan 28, 2020, with participation from 0 investor.

Where does Tetraphase Pharmaceuticals rank among its competitors?

Tetraphase Pharmaceuticals ranks 32nd amongst 202 active competitors, of which 76 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Among them, Vedanta Biosciences secured the most recent funding round in February, 2024.

Tetraphase Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Tetraphase Pharmaceuticals is an acquired company based in Watertown (United States), founded in 2006. It operates as an US-based, public, clinical-stage biopharma developing tetracycline analogs for multidrug-resistant infections.. Tetraphase Pharmaceuticals has raised $80M in funding from Excel Medical Ventures and F-Prime Capital. The company has 202 active competitors, including 76 funded and 39 that have exited. Its top competitors include companies like Spero Therapeutics, Vedanta Biosciences and Paratek Pharma.

Company Details

Tetraphase is a US-based, public, clinical-stage biopharma developing tetracycline analogs for multidrug-resistant infections. The company has developed a proprietary chemistry technology to create novel analogs of Tetracycline, that were previously inaccessible structural variability. With this technology, the company has created a library of over 2500 compounds that it is currently screening against various bacterial targets. Its lead product candidate is Eravacycline, a novel, fully-synthetic fluorocycline antibiotic. Eravacycline is in phase 3 clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Website: tphase.com
Social
Email ID: *****@tphase.com
Phone Number: +1 **********

Key Metrics

Founded Year

2006

Location

Watertown, United States

Stage

Acquired

Total Funding

$80M in 5 rounds

Latest Funding Round

Post IPO, Jan 28, 2020, $*****

Investors

Excel Medical Ventures & 10 more

Ranked

32^nd among 202 active competitors

Employee Count

31 as on Dec 31, 2020

Similar Companies

Spero Therapeutics & 254 more

Exit Details

Acquired by La Jolla Pharmaceutical (Jun 24, 2020)

View Tetraphase Pharmaceuticals' full profile

Tetraphase Pharmaceuticals got acquired by La Jolla Pharmaceutical on Jun 24, 2020 at an acquisition amount of $*****.

Click here to take a look at Tetraphase Pharmaceuticals's acquisition in detail

Tetraphase Pharmaceuticals has raised a total funding of $80M over 5 rounds. Its first funding round was on Nov 2006. Tetraphase Pharmaceuticals has 11 institutional investors.

Here is the list of recent funding rounds of Tetraphase Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2020	8421032	Post IPO	1254109	8600587	2012435	8633750
May 28, 2010	2490546	Series C	9984869	1140254	9891333	CMEA Capital & 4 more
Sep 22, 2009	9768962	Series B	8429627	6256236	F-Prime Capital	Mediphase Venture Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Tetraphase Pharmaceuticals's funding rounds and investors

Tetraphase Pharmaceuticals' employee count trend

Tetraphase Pharmaceuticals has 31 employees as of Dec 20. The total employee count is 60.0% lower than what it was in Dec 19. Here is Tetraphase Pharmaceuticals's employee count trend over the years:

Employee count trend for Tetraphase Pharmaceuticals

Uncover Tetraphase Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tetraphase Pharmaceuticals include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Here is the list of Top 10 competitors of Tetraphase Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Partners Health Care Innovation, Atlas Venture ... & 16 others	72/100
2nd	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
3rd	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Aisling Capital, Phase4 Partners & 23 others	64/100
4th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	62/100
5th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	61/100
6th	Aelin Therapeutics 2017, Leuven (Belgium), Series A	Developer of antibiotics based on protein aggregation approach	$31.8M	Life Sciences Partners, Boehringer Ingelheim Venture Fund ... & 5 others	61/100
7th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Janchor Partners & 12 others	61/100
8th	Cubist Pharmaceuticals 1993, Lexington (United States), Acquired	Developing drugs to treat a range of acute care related diseases	-	Vivo Capital, Cardinal Partners & 2 others	61/100
9th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	60/100
10th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Viking Global Investors, Artis Ventures & 13 others	60/100
32nd	Tetraphase Pharmaceuticals 2006, Watertown (United States), Acquired	US-based, public, clinical-stage biopharma developing tetracycline analogs for multidrug-resistant infections.	$80M	F-Prime Capital, Eight Roads Ventures & 9 others	51/100